Analysts Set INmune Bio, Inc. (NASDAQ:INMB) PT at $18.40

Key Points

• INmune Bio, Inc. has received a consensus rating of "Moderate Buy" from seven brokerages, with analysts giving a mix of ratings including one sell, two hold, three buy, and one strong buy.
• The average price target among analysts for INmune Bio is $18.40, despite recent downgrades from some firms, including a cut from $30.00 to $8.00 by Maxim Group.
• INmune Bio reported an EPS of ($0.34) for the last quarter, exceeding the consensus estimate of ($0.37), while analysts anticipate a total earnings per share of -2.24 for the current fiscal year.

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $18.40.

Several equities analysts recently issued reports on INMB shares. BTIG Research reiterated a "neutral" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Wall Street Zen cut INmune Bio from a "hold" rating to a "sell" rating in a research report on Saturday, August 2nd. Maxim Group cut their price objective on INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, July 2nd. Scotiabank reaffirmed a "sector underperform" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Finally, Raymond James Financial lowered INmune Bio from a "moderate buy" rating to a "hold" rating in a research report on Monday, June 30th.

Institutional Investors Weigh In On INmune Bio

Hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC bought a new stake in shares of INmune Bio during the second quarter valued at approximately $26,000. PFG Investments LLC purchased a new position in INmune Bio during the 2nd quarter valued at about $27,000. Wells Fargo & Company MN lifted its position in INmune Bio by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock valued at $30,000 after acquiring an additional 2,155 shares during the period. Modera Wealth Management LLC purchased a new position in INmune Bio during the 2nd quarter valued at about $36,000. Finally, Beacon Pointe Advisors LLC purchased a new position in INmune Bio during the 4th quarter valued at about $48,000. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Trading Up 2.6%

Shares of INMB stock traded up $0.06 during mid-day trading on Wednesday, reaching $2.41. The stock had a trading volume of 644,216 shares, compared to its average volume of 2,468,215. The stock's 50-day moving average price is $3.35 and its two-hundred day moving average price is $6.27. INmune Bio has a 52-week low of $1.89 and a 52-week high of $11.64. The firm has a market capitalization of $64.06 million, a PE ratio of -0.97 and a beta of 0.97.

INmune Bio (NASDAQ:INMB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. On average, equities research analysts forecast that INmune Bio will post -2.24 earnings per share for the current year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.